News | Lung Imaging | January 27, 2016

Mayo Clinic study finds group still at high risk for lung cancer but does not currently qualify for screening

Mayo Clinic study, low-dose CT screening, lung cancer, heavy smokers

January 27, 2016 — Expanding lung cancer screening to include people who quit smoking more than 15 years ago could detect more cases and further reduce associated mortality, according to a study by Mayo Clinic researchers published in the Journal of Thoracic Oncology.

“A decline in smoking rates has been, and continues to be, a critical step to reduce lung cancer risk and deaths,” said the study’s lead author Ping Yang, M.D., Ph.D., an epidemiologist at Mayo Clinic Cancer Center. “But, it also means that fewer people have benefited from early detection of lung cancer, because more patients don’t qualify for low-dose CT [computed tomography] scans.” The current lung cancer screening criteria set by the U.S. Preventive Services Task Force (USPSTF) recommends CT screening for adults between the ages of 55 and 80 who have smoked at least one pack a day for 30 years and are still smoking, or have quit within 15 years.

In a study published in JAMA in 2015, Yang and her colleagues found that two-thirds of patients in the United Stats with newly diagnosed lung cancer would not meet the current USPSTF screening criteria, suggesting a need to adjust the definition of patients at high risk.

In the current study, Yang and her colleagues set out to identify which specific populations of individuals are at risk, but are being missed by the current lung cancer screening criteria. Researchers retrospectively tracked two groups of people with lung cancer: a hospital cohort made up of 5,988 individuals referred to Mayo Clinic and a community cohort consisting of 850 residents of Olmsted County, Minn.

They found that, compared to other risk categories, patients who quit smoking for 15 to 30 years accounted for the greatest percentage of patients with lung cancer who didn’t qualify for screening. The newly defined high-risk group constituted 12 percent of the hospital cohort and 17 percent of the community cohort.

“We were surprised to find that the incidence of lung cancer was proportionally higher in this subgroup, compared to other subgroups of former cigarette smokers,” said Yang. “The common assumption is that after a person has quit for so many years, the lung cancer rate would be so low that it wouldn’t be noticeable. We found that assumption to be wrong. This suggests we need to pay attention to people who quit smoking more than 15 years ago, because they are still at high risk for developing lung cancer.”

Equally important, the current study found that expanding the criteria for CT screening would not significantly add to the number of false-positive cases and would save more lives with an acceptable amount of radiation exposure and cost. Yang and her colleagues showed that expanding the criteria to include this risk category could add 19 percent more CT examinations for detecting 16 percent more cases. They calculated the expansion would result in minimal increases in false-positive results (0.6 percent), over diagnosis (0.1 percent) and radiation-related lung cancer deaths (4 percent).

"Lung cancer rates are dropping, because smoking is decreasing, but that doesn’t mean that our current screening parameters are good enough,” Yang said. “It is understandable, because the relative importance of risk factors changes over time. We need to adjust screening criteria periodically, so we can catch more lung cancers in a timely fashion. Based on our data, which are more recent and come from a well-defined population, I think that we should take action to screen this group, which is at high risk of developing the disease.”

She recommends additional research to confirm if similar trends are being seen in populations beyond Olmsted County, Minn. If confirmed, she recommends that policymakers consider changing the lung cancer screening guidelines to include people who quit smoking more than 15 years ago. She also recommends that policymakers continue to re-examine lung cancer screening criteria to account for changes in groups that are most at risk.

Co-authors are:

  • Jason Wampfler, Mayo Clinic;
  • Shawn Stoddard, Mayo Clinic;
  • David Midthun, M.D., Mayo Clinic;
  • Yi Wang, M.D., Wenzhou Medical University, China;
  • Dong Xie, M.D., Ph.D., Shanghai Pulmonary Hospital, China; and
  • Jun She, M.D., Ph.D., Shanghai Respiratory Institute, Fudan University, China.

For more information: www.mayoclinic.org


Related Content

News | PET-CT

June 19, 2025 — Building on a collaboration that spans more than three decades, GE HealthCare has renewed its research ...

Time June 19, 2025
arrow
News | Lung Imaging

April, 15, 2025 — Optellum has entered an agreement with Bristol Myers Squibb to leverage AI in early diagnosis and ...

Time April 17, 2025
arrow
News | Pediatric Imaging

April 10, 2025 — Cincinnati Children’s and GE HealthCare will form a strategic research program focused on driving ...

Time April 10, 2025
arrow
News | SPECT Imaging

Feb. 5, 2025 — Serac Healthcare Ltd., a clinical radiopharmaceutical company developing an innovative molecular imaging ...

Time February 05, 2025
arrow
News | Computed Tomography (CT)

Dec. 3, 2024 — During RSNA '24, GE HealthCare announced the 510(k) submission to the U.S. Food and Drug Administration ...

Time December 18, 2024
arrow
News | SPECT Imaging

Dec. 2, 2024 — GE HealthCare has agreed to acquire full ownership of Nihon Medi-Physics Co., Ltd (NMP), by purchasing ...

Time December 05, 2024
arrow
News | Artificial Intelligence

Sept. 13, 2024 — Bayer Calantic Digital Solutions has announced the availability of a new eBook that addresses how ...

Time September 12, 2024
arrow
News | Computed Tomography (CT)

At the annual AHRA (American Healthcare Radiology Administrators) conference in Orlando, Florida, Bayer announced an ...

Time August 09, 2024
arrow
Videos | Radiology Business

Find actionable insights to achieve sustainability and savings in radiology in this newest of ITN’s “One on One” video ...

Time July 30, 2024
arrow
News | Radiology Business

July 25, 2024 — Immunis, Inc., a clinical-stage biotech developing groundbreaking secretome therapeutics for age and ...

Time July 25, 2024
arrow
Subscribe Now